- Home
- PRME vs DDI Comparison
PRME vs DDI Comparison
Compare PRME & DDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | DDI |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | South Korea |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.2M | 607.0M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRME | DDI |
|---|---|---|
| Price | $3.54 | $12.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.56 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 2.4M | 113.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | $6.65 |
| Revenue Next Year | $47.01 | $2.64 |
| P/E Ratio | ★ N/A | $4.31 |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $8.10 |
| 52 Week High | $6.94 | $13.28 |
Technical Indicators
Market Signals| Indicator | PRME | DDI |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 57.51 |
| Support Level | $3.16 | $12.60 |
| Resistance Level | $3.69 | $13.28 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 51.13 | 23.53 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.